Reuters logo
9 months ago
BRIEF-AbbVie announces positive pivotal phase 3 data for elagolix
October 19, 2016 / 1:20 PM / 9 months ago

BRIEF-AbbVie announces positive pivotal phase 3 data for elagolix

1 Min Read

Oct 19 (Reuters) - Abbvie Inc

* AbbVie announces positive pivotal phase 3 data demonstrating investigational medicine elagolix reduces menstrual and non-menstrual pelvic pain associated with endometriosis at the American Society for reproductive medicine scientific congress

* Elagolix shows superiority compared to placebo in reducing daily menstrual and non-menstrual pelvic pain associated with endometriosis

* FDA new drug application anticipated in 2017

* Elagolix shows superiority compared to placebo in reducing daily menstrual and non-menstrual pelvic pain associated with endometriosis Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below